drugset
drugset / Trial / NCT00329966

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older

NCT00329966 ↗

Phase 2 Completed 100 enrolled Novartis Novartis Vaccines · collab
Non-randomizedSingle-groupOpen-labelPrevention

Summary

To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over

Timeline

Start
2006-06
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject SPUNOLEUCEL Vaccine — —

Indications

influenza